Roth Capital Initiates Coverage On Repligen with Buy Rating, Announces Price Target of $160

Benzinga Newsdesk www.benzinga.com Neutral 57.5%

Neg 0% Neu 57.5% Pos 0%

Roth Capital analyst Natalya Davies initiates coverage on Repligen (NASDAQ:RGEN) with a Buy rating and announces Price Target of $160.